Novartis
NVS
NVS
1,327 hedge funds and large institutions have $12.9B invested in Novartis in 2024 Q4 according to their latest regulatory filings, with 153 funds opening new positions, 418 increasing their positions, 465 reducing their positions, and 106 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
1,327
Holders Change
+24
Holders Change %
+1.84%
% of All Funds
17.67%
Holding in Top 10
9
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-30.77%
% of All Funds
0.12%
New
153
Increased
418
Reduced
465
Closed
106
Calls
$190M
Puts
$250M
Net Calls
-$60.3M
Net Calls Change
+$63M
Top Buyers
| 1 |
D.E. Shaw & Co
New York
|
+$54.9M |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$46.4M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$39.5M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$38.9M |
| 5 |
Renaissance Technologies
New York
|
+$35.8M |
Top Sellers
| 1 |
Goldman Sachs
New York
|
-$117M |
| 2 |
Primecap Management
Pasadena,
California
|
-$95.7M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$86.5M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$40.4M |
| 5 |
MIP
Mondrian Investment Partners
London,
United Kingdom
|
-$35.8M |
